RheumMadness 2025: The Innovation Invitational

The competition was tough. I feel BiTes have the potential to have the biggest impact. CAR-T is impressive but too risky and expensive to have a wide impact. TYK2 but not just for SLE was a close second. And CD40L would be welcome to treat a disease with very few options.